RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $252

Benzinga Newsdesk www.benzinga.com Positive 90.1%

Neg 0% Neu 0% Pos 90.1%

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $235 to $252.